NPC Archive Item: Sibutramine (Reductil) licence suspended throughout Europe

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 22 January 2010 The MHRA has announced that the licence for sibutramine has been suspended throughout Europe. This follows a review which considered the increased risk of non-fatal heart […]

NPC Archive Item: FDA reviews the safety of Orlistat

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 22 September 2009 The FDA is reviewing the safety information for Orlistat following reports of serious liver injury. However, no definite association between liver injury and orlistat has been […]

NPC Archive Item: Rimonabant marketing authorisation to be suspended

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The MHRA has announced the Europe-wide suspension of the Marketing Authorisation for rimonabant▼ (Acomplia®) following recommendations from the EMEA’s Committee for Medicinal Products for Human Use (CMHP). The CMHP […]

NPC Archive Item: NICE Final Appraisal Determination recommends rimonabant▼

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. NICE has published a Final Appraisal Determination (FAD) for rimonabant▼ for the treatment of overweight and obese patients. In the Appraisal Consultation Document, published in December 2007, the Appraisal […]

NPC Archive Item: Preliminary recommendations from NICE reject rimonabant

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Preliminary recommendations from NICE reject rimonabant The NICE Appraisal Committee has developed preliminary recommendations on the use of rimonabant for the treatment of overweight and obese adults, which state […]

NPC Archive Item: Rimonabant and psychiatric side effects

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370:1706-1713. Why is this of concern? […]